U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07478471) titled 'Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax' on July 21, 2025.
Brief Summary: This observational, open-label, single arm, study is designed such that it may be implemented for any individual with a lab confirmed sporadic case of systemic anthrax disease treated with raxibacumab outside of the current United States Prescribing Information (USPI). Systemic anthrax cases may include inhalational, gastrointestinal and injectional anthrax, anthrax meningitis or bacteremia or cutaneous anthrax with systemic effects.
This study is designed to evaluate the clinical effectiveness (including course of illness an...